Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06602687

PICSI Impact on Euploidy in Assisted Reproduction

Hyaluronic acid (HA) is a major component of the cumulus complex surrounding oocytes. Intracytoplasmic sperm injection (ICSI) involves injection of a selected sperm into the oocyte. Embryologists select sperm with normal morphology and progressive motility. Physiologic intracytoplasmic sperm injection (PICSI) involves sperm selection for ICSI based on hyaluronan binding. Mature sperm which bind to HA have greater genomic integrity and reduced levels of DNA fragmentation. Earlier observational studies demonstrated improved outcomes in assisted reproductive technologies (ART) including improved clinical pregnancy rates, decreased miscarriage rates and higher live birth rates. A large multicentre randomized trial, the HABSelect trial, which included over 2,500 couples, found that PICSI did not improve term (>37 weeks gestation) live birth rates compared to standard ICSI. However, mechanistic analysis of the data from the HABSelect trial showed a significant reduction in miscarriage rates, most notable in couples where the woman was aged over 37 years where a significant reduction in miscarriage rate was seen (40% with ICSI vs 15% with PICSI). A 2021 retrospective sibling oocyte study, including 45 cycles, compared fertilisation and embryo development and found higher fertilisation rate in PICSI cycles. No difference was observed in clinical pregnancy rates; miscarriage rates and live birth rates were not reported. We aim to prospectively study PICSI vs standard ICSI in sibling oocytes to investigate if PICSI improves embryological and ART outcomes, particularly fertilisation rate, embryo euploid status and miscarriage rate, where the female patient is aged over 35 years.

Recruiting

Interested in participating?

Request Info

Key information

Age range

35 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Merrion Fertility Clinic

Dublin, D02 NH93, Ireland

Location status: Recruiting

Location contact

David Crosby, MD

CONTACT

Louise E Glover, PhD

CONTACT

[email protected]

353 + 15567900

Louise Glover, PhD

CONTACT

Sarah Petch, MD

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Couples undergoing a planned ICSI-PGT-A cycle using their own fresh gametes
  • Female age > 35 years and/or Male age > 40 years
  • Minimum of two mature eggs at time of egg maturity assessment

Exclusion criteria

  • Couples undergoing a planned IVF cycle (even if converted to ICSI)
  • Patients using donor gametes for an ICSI cycle
  • Patients using frozen gametes for an ICSI cycle

Treatment and study plan

PICSI

Device

The PICSI® dish is a CE marked medical device containing dots of a HA hydrogel (Cooper Surgical).

Primary outcomes

  1. Euploidy rates

    Time frame: 4 weeks

    Primary outcome is rate of euploid embryos per cycle after preimplantation genetic testing for aneuploidy (PGT-A)

Secondary outcomes

  1. Fertilisation rates

    Time frame: 24-48 hours

    Defined as number of 2PNs per oocyte injected

  2. Blastocyst development and rate

    Time frame: 5 and 6 days

    Assessed on day 5 and day 6 according to Gardner grading system.

  3. Positive hCG rate

    Time frame: 6-7 weeks

    Defined as detection of urinary human chorionic gonadotropin (hCG) per embryo transfer cycles.

  4. Clinical pregnancy rate

    Time frame: 6-7 weeks

    Defined as number of fetal heartbeats/ gestational sacs identified by ultrasonographic visualisation at 6-7 weeks gestation per cycles started, oocyte retrievals or embryo transfer cycles.

  5. Miscarriage rate

    Time frame: up to 22 weeks

    Defined as number of spontaneous losses of an intra-uterine pregnancy prior to 22 completed weeks of gestational age per embryo transfer cycles.

  6. Live birth rate

    Time frame: 37-42 weeks

    Defined as number of live births at ≥37 weeks gestation per embryo transfer cycles

Study contacts

Contact information is provided by the study sponsor or research team.

Louise E Glover, PhD

CONTACT

[email protected]

353 + 15567900

Sponsors and collaborators

Lead sponsor

Merrion Fertility Clinic

Other

Registry information

Official study title

Sperm Hyaluronic Binding Selection (PICSI): Impact on Embryo Aneuploid Status in Assisted Human Reproduction

Important dates

Study start
2024
Primary completion
2026
Study completion
2029
First posted
Sep 19, 2024
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.